New antiemetic combination for chemotherapy-induced nausea and vomiting

Akynzeo (netupitant/palonosetron) is a new option for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy or moderately emetogenic chemotherapy.

A single capsule of Akynzeo is given approximately 1 hour before the start of each chemotherapy cycle.
A single capsule of Akynzeo is given approximately 1 hour before the start of each chemotherapy cycle.

Further information
View Akynzeo drug record
Summary of Product Characteristics
Manufacturer: Chugai

The single-dose Akynzeo capsule contains the neurokinin NK1 antagonist netupitant (300mg) and the 5HT3 antagonist palonosetron (500 microgram). 

Pivotal studies

Oral administration of the combination with concomitant dexamethasone was shown in two pivotal studies to prevent nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in chemotherapy-naïve patients.

Highly emetogenic chemotherapy

A randomised, double-blind study in 694 patients undergoing cisplatin-based chemotherapy for solid tumours compared three doses of netupitant (100mg, 200mg, and 300mg) plus palonosetron 500 microgram with oral palonosetron 500 microgram alone, all given as single doses on day 1. The primary efficacy endpoint was complete response (defined as no emesis and no rescue medication) for the period 0–120 hours after the start of cisplatin infusion.

At all netupitant doses, the combination produced higher complete response rates than palonosetron alone (87.4%, 87.6%, and 89.6% for netupitant 100mg, 200mg, and 300mg, respectively, vs 76.5% for palonosetron; p<0.050), with the 300mg dose showing an advantage over lower doses for all efficacy endpoints. 

Moderately emetogenic chemotherapy

A second randomised, double-blind study in 1455 patients receiving moderately emetogenic (anthracycline–cyclophosphamide) chemotherapy compared a single dose of netupitant 300mg and palonosetron 500 microgram with a single dose of 500 microgram palonosetron. The primary efficacy endpoint was complete response during the delayed phase (25–120 hours after the start of chemotherapy) in cycle 1.

The percentage of patients who experienced a complete response during the delayed phase was significantly higher in the combination group than in the palonosetron-only group (76.9% vs 69.5%; p=0.001), as were the percentages in the overall (0–120 hours) and acute (0–24 hours) phases (respectively, 74.3% vs 66.6%; p=0.001 and 88.4% vs 85.0%; p=0.047).

Safety profile

The combination of netupitant and palonosetron was well tolerated, with a similar safety profile to that of palonosetron alone. Common adverse reactions reported were headache (3.6%), constipation (3.0%) and fatigue (1.2%).

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.